These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20724671)

  • 1. HPV vaccination's second act: promotion, competition, and compulsion.
    Schwartz JL
    Am J Public Health; 2010 Oct; 100(10):1841-4. PubMed ID: 20724671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
    Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
    Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warts and all at last: HPV vaccination.
    Hammond P
    BMJ; 2011 Nov; 343():d7779. PubMed ID: 22131211
    [No Abstract]   [Full Text] [Related]  

  • 7. The HPV vaccine controversy.
    Intlekofer KA; Cunningham MJ; Caplan AL
    Virtual Mentor; 2012 Jan; 14(1):39-49. PubMed ID: 23116916
    [No Abstract]   [Full Text] [Related]  

  • 8. Gardasil: Introducing the new human papillomavirus vaccine.
    McLemore MR
    Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the new HPV vaccines in clinical practice.
    Widdice LE; Kahn JA
    Cleve Clin J Med; 2006 Oct; 73(10):929-35. PubMed ID: 17044318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy.
    Handler NS; Handler MZ; Majewski S; Schwartz RA
    J Am Acad Dermatol; 2015 Nov; 73(5):759-67; quiz 767-8. PubMed ID: 26475535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.
    Fruscalzo A; Londero AP; Bertozzi S; Lellè RJ
    Minerva Med; 2016 Feb; 107(1):26-38. PubMed ID: 26473283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Australian experience with the human papillomavirus vaccine.
    Garland SM
    Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current immunization committee includes vaccination against human papillomaviruses in the immunization schedule].
    Kinderkrankenschwester; 2007 May; 26(5):205. PubMed ID: 17550093
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
    Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV vaccine strategies: the cost of HPV and the choice of vaccine.
    Morris SR
    Sex Transm Infect; 2009 Sep; 85(5):315-6. PubMed ID: 19773455
    [No Abstract]   [Full Text] [Related]  

  • 20. A human papillomavirus vaccine.
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):65-6. PubMed ID: 16977280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.